| Accession |
PRJCA010798 |
| Title |
a phase II clinical study of fluzoparib in combination with camrelizumab and rivoceranib in recurrent platinum resistant ovarian cancer |
| Relevance |
Medical |
| Data types |
clinical,image,biomarker,Genetic,
|
| Organisms |
Homo sapiens
|
| Description |
The main purpose of:To evaluate the efficacy of fluzoparib combined with carrelizumab and apatinib in relapsed platinum resistant ovarian cancer.A secondary purpose:To evaluate the safety of fluzoparib combined with carrelizumab and apatinib in relapsed platinum resistant ovarian cancer. |
| Sample scope |
Multiisolate |
| Release date |
2024-07-26 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Jiangsu Hengrui Pharmaceutical Co. LTD
|
|
OBUOvaCMUL-IIT-SHR1210-APA-FZPL
|
|
|
|
| Submitter |
Jia
Ao
Pan (jiaao.pan@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2022-07-26 |
